Inflammatory Plasma Markers and Pancreatic Cancer Risk: a Prospective Study of 5 U.S. Cohorts
Couplée aux données de cinq cohortes américaines (470 cas et 1 094 témoins), cette étude prospective évalue l'association entre des marqueurs d'une inflammation chronique mesurés dans le plasma et le risque de cancer du pancréas
Background: Chronic inflammation may play a role in the development of pancreatic cancer. However, few prospective studies have examined the association between plasma inflammatory markers and pancreatic cancer risk. Methods: In a prospective, nested case-control study of 470 cases and 1094 controls from Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study, we investigated the association of prediagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-α-receptor II (TNF-αR2) with subsequent pancreatic cancer risk. The median follow-up time of cases was 7.2 years (range 1-26 years). Results: No association was observed between plasma CRP, IL6, and TNF-αR2 and risk of pancreatic cancer. Comparing extreme quintiles, the multivariate ORs were 1.10 (95% CI, 0.74-1.63; Ptrend= 0.81) for CRP, 1.19 (95% CI, 0.81-1.76; Ptrend = 0.08) for IL6, and 0.88 (95% CI, 0.58-1.33; Ptrend = 0.57) for TNF-αR2. Conclusions: Pre-diagnostic levels of circulating CRP, IL6, and TNF-αR2 were not associated with risk of pancreatic cancer. Impact: Systemic inflammation as measured by circulating inflammatory factors is unlikely to play a major role in the development of pancreatic cancer.